Topical application of clobetasol-17-propionate inhibits the intra-epidermal accumulation of polymorphonuclear leukocytes.
The in vivo effect of topical clobetasol-17-propionate (CP) on the leukotriene B4- and trauma-induced intra-epidermal accumulation of polymorphonuclear leukocytes (PMN) was investigated in normal volunteers. PMN accumulation was assessed using elastase, a specific and sensitive marker for these cells. A profound inhibition of PMN accumulation was shown in the first 2 days of treatment with CP, an effect that faded away after a treatment of 2 weeks.
D000287:Administration, Topical; D000328:Adult; D001623:Betamethasone / Q000031:analogs & derivatives*; D002990:Clobetasol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D007975:Leukotriene B4 / Q000032:analysis; D008297:Male; D009504:Neutrophils / Q000187:drug effects*; D012867:Skin / Q000293:injuries / Q000473:pathology*
D007975:Leukotriene B4; D001623:Betamethasone; D002990:Clobetasol